Appeal filed against EPO sofosbuvir patent decision
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
FDA to focus on data in new ‘top strategic priority’
The US Food and Drug Administration has announced a new strategy for the use of “real-world evidence” and “real-world data” to improve its regulation of new drugs.
European pharma body criticises SPC waiver vote
The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
GE Healthcare files patent lawsuit against Bio-Rad
American conglomerate GE Healthcare last week filed a lawsuit against California-based life sciences company Bio-Rad Laboratories on four counts of patent infringement.
Allele Biotech partners with Scientist.com to develop nanoantibodies
US-based Allele Biotechnology & Pharmaceuticals, a preclinical-stage biopharmaceutical company, has teamed up with a scientific e-commerce marketplace network in efforts to develop nanoantibodies for therapeutic applications.
UK life sciences partnership to use AI in disease detection
The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
Boehringer in research collaboration with Domain Therapeutics
German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.
GSK seeks to boost oncology repertoire with $5.1bn acquisition
GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
AbbVie and Pfizer in Humira licensing deal
AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
EFPIA concerned over SPC waiver amendments
Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.
